Search Results - "Ferraris, Matias"

Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study by Tepper, Stewart J., Fang, Juanzhi, Vo, Pamela, Shen, Ying, Zhou, Lujia, Abdrabboh, Ahmad, Glassberg, Mrudula, Ferraris, Matias

“…Background Migraine is one of the leading causes of disability worldwide. Erenumab is a fully human monoclonal antibody that targets the calcitonin…”
Get full text

Correction to: Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis by Fang, Juanzhi, Korrer, Stephanie, Johnson, Jonathan C., Cheadle, Mark A., Shah, Roshani, Ferraris, Matias L., Lopez-Lopez, Cristina

Get full text

Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis by Fang, Juanzhi, Korrer, Stephanie, Johnson, Jonathan C., Cheadle, Mark A., Shah, Roshani, Ferraris, Matias L., Lopez-Lopez, Cristina

“…Introduction This retrospective analysis aimed to characterize patients with migraine initiating erenumab and the shifting or trend of patient characteristics…”
Get full text

Correction to: Real-World Trends in Characteristics of Patients with Migraine Newly Initiated on Erenumab in the USA: A Retrospective Analysis by Fang, Juanzhi, Korrer, Stephanie, Johnson, Jonathan C., Cheadle, Mark A., Shah, Roshani, Ferraris, Matias L., Lopez-Lopez, Cristina

“…A correction to this paper has been published: https://doi.org/10.1007/s12325-021-01744-4…”
Get full text

Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison by Mahon, Ronan, Tiwari, Santosh, Koch, Mirja, Ferraris, Matias, Betts, Keith A, Wang, Yan, Gao, Sophie, Proot, Pascal

“…To compare the efficacy of erenumab versus rimegepant as preventive treatment for patients with episodic and chronic migraine using an anchor-based…”
Get full text

Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study by Tepper, Stewart J, Fang, Juanzhi, Zhou, Lujia, Vo, Pamela, Abdrabboh, Ahmad, Glassberg, Mrudula, Ferraris, Matias

“…Background: Erenumab, a fully human monoclonal antibody targeting the calcitonin gene-related peptide pathway, was developed specifically for preventive…”
Get full text

Management of Migraine and the Accessibility of Specialist Care: Findings from an Extended Multinational Survey (My Migraine Center Survey) by Wongsiriroj, Siriporn, Grillo, Elisabetta, Levi, Sabrina, Zielman, Ronald, Lahouiri, Elia, Marchina, Marco, Pedrazzoli, Marco, Ferraris, Matias

“…Introduction The parent study was a survey in 28 headache centers (6 countries) which identified five potential root causes for long waiting lists that limit…”
Get full text

Comparative Effectiveness of Erenumab versus Oral Preventive Medications among Migraine Patients: A US Claims Database Study (1821) by Tepper, Stewart, Fang, Juanzhi, Zhou, Lujia, Vo, Pamela, Abdrabboh, Ahmad, Glassberg, Mrudula, Ferraris, Matias

“…Abstract only…”
Get full text

Real-World Healthcare Costs and Resource Utilization Among Patients Treated With Erenumab in the United States: A Retrospective Claims Database Study (P16-7.003) by Tepper, Stewart, Schwedt, Todd, Vo, Pamela, Joshi, Parth, Glassberg, Mrudula, Abdrabboh, Ahmad, Ferraris, Matias, Tiwari, Santosh, Thompson, Jeffrey

“…Abstract only…”
Get full text

Real-world treatment satisfaction with erenumab in migraine: analysis of the US National Health and Wellness Survey by Pathak, Purnima, Yue, Leiyu, Gupta, Shaloo, Fang, Juanzhi, Cheadle, M. Andy, Tiwari, Santosh, Ferraris, Matias, Joshi, Parth, Thompson, Jeffrey, Shah, Roshani, Vo, Pamela

“…The treatment landscape for the prevention of migraine has rapidly evolved in recent years with the advent of calcitonin gene-related peptide therapy,…”
Get full text

Healthcare costs and resource utilization in patients with migraine treated with erenumab: A retrospective, non‐interventional study using claims data from the United States by Tepper, Stewart J., Schwedt, Todd J., Vo, Pamela, Thompson, Jeffrey, Joshi, Parth, Abdrabboh, Ahmad, Ferraris, Matias, Tiwari, Santosh

“…Objective To assess healthcare costs and healthcare resource utilization (HCRU) among adult patients who newly initiated erenumab in the United States. Methods…”
Get full text

Assessment of the relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine by Mahon, Ronan, Vo, Pamela, Pannagl, Katharina, Tiwari, Santosh, Heemstra, Harald, Ferraris, Matias, Zhao, Jing, Betts, Keith A., Proot, Pascal

“…To assess the available clinical and economic evidence of erenumab vs onabotulinumtoxinA for chronic migraine (CM) and present de-novo indirect treatment…”
Get full text

Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States by Tepper, Stewart J, Fang, Juanzhi, Zhou, Lujia, Shen, Ying, Vo, Pamela, Abdrabboh, Ahmad, Glassberg, Mrudula B, Ferraris, Matias

“…Migraine is a common neurological disease that can have a substantial impact on patients' lives and on society. Erenumab, a fully human monoclonal antibody…”
Get full text